openPR Logo
Press release

Launch of Groundbreaking Cancer Detection Platform Flamingo with Nvidia AI Computing Power, Plus Plans to Acquire 100% Ownership of Cyclomics: Renovaro Inc. (Nasdaq: RENB)

04-30-2024 10:00 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Getnews

/ PR Agency: CAP, LLC
Launch of Groundbreaking Cancer Detection Platform Flamingo

$RENB Working with $NVDA and Oxford Nanopore for Sequencing Technology and Front Edge Software Solutions
- Focus on Personalized Medicine for Longevity Powered by Mutually Reinforcing AI and Biotechnology Platforms.

- Plans to Acquire 100% of Cyclomics for Shared Commitment to Advancing State-of-the-Art Technologies in Cancer Diagnostics and Treatment.

- Relationships with Oxford Nanopore & Nvidia position RENB as a Leader in Early Cancer Diagnostics and Monitoring Treatment Efficacy.

- Introduced Flamingo, a Potentially Groundbreaking Multi-Cancer Detection Model to Transform Early Cancer Diagnostics.

Renovaro, Inc (Nasdaq: RENB) aims to accelerate precision and personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better-targeted treatments, and drug discovery. RENB includes Renovaro Bio with its advanced cell-gene immunotherapy company and RenovaroCube. RenovaroCube has developed an award-winning AI platform that is committed to the early detection of cancer and its recurrence and monitoring subsequent treatments. RenovaroCube intervenes at a stage where potential therapy can be most effective. RenovaroCube is a molecular data science company with a background in FinTech and a 10-year history. RENB brings together proprietary artificial intelligence (AI) technology, multi-omics, multi-modal data, and the expertise of a carefully selected multidisciplinary team to radically accelerate precision medicine and enable breakthrough changes in cancer care.

Upon the closing of the acquisition of Cyclomics (winner of the Health Holland Venture Challenge), RenovaroCube will be capable of performing liquid biopsies using proprietary technologies to identify single cancer DNA molecules in only one vial of blood. In combination with Oxford Nanopore Technology, genetic information can be retrieved over multiple genetic layers to develop the next generation of cancer diagnostics. This has the potential to transform cancer care by enabling faster and more accurate diagnosis throughout the patient journey.

RENB has announced a significant milestone in their collaboration. RenovaroCube has entered into an amendment to its binding letter of intent to acquire 100% ownership of Cyclomics, further cementing their shared commitment to advancing state-of-the-art technologies in cancer diagnostics and treatment. Their combined relationships with Oxford Nanopore and Nvidia will further position RENB RenovaroCube to be a leader in early cancer diagnostics and monitoring of treatment efficacy. Oxford Nanopore is a leader in sequencing technologies and Nvidia will provide vital supercomputing power and front-edge software solutions such as Parabricks, BioNeMo, Monai, and Nemo.

Initially set at a 75% acquisition, this decision to acquire the remaining 25% of Cyclomics reflects the resounding success of their partnership and the remarkable synergy between the two companies. Upon closing, RENB believes the acquisition of Cyclomics into the Renovaro family will further strengthen its ability to create a powerhouse for cancer diagnostics throughout the entire patient journey, from early detection/recurrence and personalized treatment in late-stage disease

Transforming Cancer Detection: RenovaroCube Introduces Flamingo, a Novel AI Model Based on Fragmentomics

On April 30th RENB unveiled its Flamingo, a potentially groundbreaking multi-cancer detection model contributing to its mission to transform early cancer diagnostics. Leveraging ultra-low pass whole genome sequencing (ULP-WGS) of cell-free DNA (cfDNA), Flamingo represents a promising leap forward in the fight against cancer.

Traditional cancer detection methods often fall short in identifying cancers at an early stage when treatment is the most effective. However, the RENB Flamingo has the potential to overcome these limitations by harnessing the power of AI to analyze minute amounts of cfDNA data that is highly accurate.

"At RenovaroCube, we believe in pushing the boundaries of possibility," states Daan Vessies, senior scientist at RenovaroCube. "Flamingo underscores our commitment to change cancer diagnostics in a transformative way, ultimately offering clinicians a powerful tool to detect cancer across diverse omic layers."

RENB believes that no single model or molecular modality will reach the requisite sensitivity and specificity throughout the entire patient journey for personalized, precision medicine, from early detection to predicting the effectiveness of various treatment options, to monitoring the response to therapy within days of starting it, to detecting recurrence at the earliest possible moment. Therefore, our AI/machine learning platform, The RENB Cube, integrates multi-omic data, offering a uniquely comprehensive approach to cancer detection by leveraging a library of trained models for multiple omic layers. One such model Flamingo focuses on is the detection of cancer from ultra-low pass whole genome sequencing (ULP-WGS) cfDNA data using fragmentomics.

The RENB Flamingo's development marks a significant milestone in the quest for early cancer detection with RenovaroCube's engine. By utilizing as few as only 200,000 cell-free DNA fragments per sample, integrating fragment lengths, and sequence motifs, and employing a meticulously designed neural network, Flamingo achieves remarkable performance in distinguishing cancer from healthy samples.

By augmenting The RENB Cube's arsenal of models operating across various omic layers, Flamingo contributes to the development of non-invasive diagnostics to detect cancer early, enabling timely interventions and improving patient outcomes.

RENB RenovaroCube invites interested doctors and scientists from international research institutions, clinical cancer centers, and all stakeholders to join in the early research use application of our AI/machine learning platform to advance cancer diagnostics and pave the way for a healthier future.

RENB Combined Companies aim to Disrupt Cancer Diagnosis and treatment through early disease and recurrence detection, prediction of response to treatment, and personalized therapy.

For more information on this Exciting NASDAQ Company: RENB visit: http://www.renovarobio.com [about:blank] and https://www.axecapitalusa.com/renb/ [about:blank]

DISCLAIMER: https://corporateads.com/disclaimer/ [about:blank]

All Disclosures listed on the www.corporateads.com
Media Contact
Company Name: Renovaro Biosciences Inc
Contact Person: The Hon. Mark Dybul, MD, CEO
Email: Send Email [http://www.universalpressrelease.com/?pr=launch-of-groundbreaking-cancer-detection-platform-flamingo-with-nvidia-ai-computing-power-plus-plans-to-acquire-100-ownership-of-cyclomics-renovaro-inc-nasdaq-renb]
Phone: 732-780-5036
Address:2080 Century Park East Suite 906
City: Los Angeles
State: California 90067
Country: United States
Website: https://www.enochianbio.com/overview/default.aspx



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Launch of Groundbreaking Cancer Detection Platform Flamingo with Nvidia AI Computing Power, Plus Plans to Acquire 100% Ownership of Cyclomics: Renovaro Inc. (Nasdaq: RENB) here

News-ID: 3481183 • Views:

More Releases from Getnews

Engel & Volkers New Smyrna Beach Welcomes John Chin as Director of Growth and Business Development
Engel & Volkers New Smyrna Beach Welcomes John Chin as Director of Growth and Bu …
Image: https://www.globalnewslines.com/uploads/2025/10/1760122468.jpg Veteran real estate leader to drive advisor productivity and fuel multi-market expansion across Central Florida NEW SMYRNA BEACH, Fla. - October 11, 2025 - Engel & Volkers Florida today announced that John Chin has joined Engel & Volkers New Smyrna Beach as Broker and Director of Growth and Business Development. With more than three decades of experience in real estate and corporate leadership, Chin will focus on boosting advisor productivity
Home Gym Deals Manchester Stands Out as One of the Best Gym Equipment Sellers in the United Kingdom
Home Gym Deals Manchester Stands Out as One of the Best Gym Equipment Sellers in …
Image: https://www.globalnewslines.com/uploads/2025/10/1760095887.jpg Home Gym Deals is recognized as the best gym equipment seller in the UK. Shop high-quality treadmills, dumbbells, benches, and more at unbeatable prices. Fast delivery and expert customer support from Manchester, UK. Manchester, UK - Home Gym Deals, a leading name in the fitness industry, continues to stand out as one of the best gym equipment sellers [https://www.homegymdeals.co.uk/] in the United Kingdom, offering an extensive range of high-quality gym
Genesis Construction and Development Launches Redesigned Website to Enhance Client Experience
Genesis Construction and Development Launches Redesigned Website to Enhance Clie …
ESSEX AND MIDDLESEX COUNTIES, MA - October 10, 2025 - Genesis Construction and Development Inc [https://www.gcdinc.us/]. is excited to announce the launch of its newly redesigned website. The enhanced digital platform reflects the company's builder-led approach and commitment to providing clients with clarity, transparency, and confidence throughout every phase of their construction journey. The refreshed website offers an improved user experience with modern design, intuitive navigation, and comprehensive information about Genesis's
Stone Oak Health Insurance Experts Announce Open Enrollment Strategies to Help San Antonio, Bulverde, and Spring Branch Residents Save on Private Health Insurance
Stone Oak Health Insurance Experts Announce Open Enrollment Strategies to Help S …
Image: https://www.globalnewslines.com/uploads/2025/10/1760089448.jpg SAN ANTONIO, TX - October 10, 2025 - With the Open Enrollment period for 2026 health plans approaching, Stone Oak Health Insurance Experts is urging residents in the Stone Oak Parkway area, Bulverde, Texas area, and Spring Branch to take a proactive approach to secure affordable and high-quality private health insurance [https://sanantoniohealthinsurance.store/]. The agency, a leader in the local San Antonio health insurance market, specializes in finding significant savings

All 5 Releases


More Releases for RENB

Milestone Merger Payment made with Predictive Oncology to Advance AI-Driven Biom …
Image: https://www.globalnewslines.com/uploads/2025/03/1741015023.jpg $RENB Secures $15 Million in New Equity to Support Operations Towards Revolutionizing Healthcare with $POAI - Developing AI and Biotechnology Platforms for Early Diagnosis, Better-Targeted Treatments and Drug Discovery. - Pioneer Leader in Cancer Diagnostics and Therapeutics Powered by Artificial Intelligence (AI). - $15 Million in New Equity Committed to accelerate Focus on Revolutionizing Healthcare via the Company's Established Strategies. - 2025 Shareholder Update Issued from CEO. - Plans to Attend American Association
Merger Agreement with BioSymetrics to Accelerate Biomarker Identification, Enhan …
Image: https://www.globalnewslines.com/uploads/2025/02/1740598477.jpg $RENB Also Secures Plus $15 Million in New Equity to Support its Operations Towards Revolutionizing Healthcare - Developing AI and Biotechnology Platforms for Early Diagnosis, Better-Targeted Treatments and Drug Discovery. - Pioneer Leader in Cancer Diagnostics and Therapeutics Powered by Artificial Intelligence (AI). - Definitive Merger Agreement with BioSymetrics to Advance AI-Driven Biomarker Discovery and Precision Medicine in Cancer and Beyond. - $15 Million in New Equity Committed to accelerate Focus on
Powerful Leadership Transition to Optimize Highly Promising AI Platform, Renovar …
- Supermajority of Shareholders Support Appointment of New CEO and the Replacement of Entire Board of Directors with Full Five-Member Slate. - Realignment to Optimize & Commercialize RenovaroCube, Disruptive AI Platform for Multi-omics Diagnostics for Cancer Early Detection and Patient Monitoring from Liquid Biopsies. - New Board Encompass Seasoned Veterans from Capital Markets, Governance, AI, Biotechnology, Cancer Detection and Treatment. - Restructuring to Accelerate Growth, Commercialization, Access to Strategic Capital and Create Long-Term
Specialist AI Team from "PersonalAIze" Highlights the Strength, Potential and Vi …
Renovaro, Inc. (Nasdaq: RENB) aims to accelerate precision and personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better-targeted treatments, and drug discovery. RENB includes RenovaroBio with its advanced cell-gene immunotherapy company and RenovaroCube. RENB RenovaroCube has developed an award-winning AI platform that is committed to the early detection of cancer and its recurrence and monitoring subsequent treatments. RenovaroCube intervenes at a stage where potential
Impressive Short Squeeze Triggered for Cancer Immunotherapy Company Renovaro, In …
Key Resistance Level Broken on June 10th Reaching Over the $2.30 Point. More Gains May Soon be on the Horizon. - $RENB uses $NVDA World Class AI Chips and Computing Power in their advancement of Early Cancer Diagnostics For more information on this Exciting NASDAQ Company: RENB visit: http://www.renovarobio.com [about:blank] and https://compasslivemedia.com/renb/ - Focus on Personalized Medicine for Longevity Powered by Mutually Reinforcing AI and Biotechnology Platforms. - New Partnership with and Signed MoU
Trailblazing AI Driven Early Cancer Diagnostics and Therapeutics for Detection w …
$RENB is Working with $NVDA and Oxford Nanopore for Sequencing Technology and Front Edge Software Solutions Renovaro Inc (Nasdaq: RENB) aims to accelerate precision and personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better-targeted treatments, and drug discovery. Renovaro includes Renovaro Bio with its advanced cell-gene immunotherapy company and RenovaroCube. RenovaroCube has developed an award-winning AI platform that is committed to the early detection